49.63 USD
↗ 0.86 (1.76%)AT CLOSE (03:59 PM EDT)
AnaptysBio, Inc. Common Stock
ANABNASDAQ • USD
49.62
↘ 0.01 (0.02%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
49.62
↘ 0.01 (0.02%)
Market: CLOSED
AnaptysBio, Inc. Common Stock (ANAB) trades at $49.66 per share. ANAB shows a split signal: technical indicators suggest "Buy" while underlying fundamentals indicate "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Oct 27, 2026.
Open?$49.24
High?$50.02
Low?$48.70
Prev. Close?$48.77
Volume?349.6K
Avg. Volume?569.2K
VWAP?$49.43
Rel. Volume?0.61x
Bid / Ask
Bid?$41.28 × 100
Ask?$60.71 × 100
Spread?$19.43
Midpoint?$51.00
Valuation & Ratios
Market Cap?1.5B
Shares Out?29.9M
Float?17.6M
Float %?59.0%
P/E Ratio?N/A
P/B Ratio?114.38
EPS?-$0.90
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Employees
104
Market Cap
1.5B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2017-01-26
Address
10770 WATERIDGE CIRCLE, SUITE 210
SAN DIEGO, CA 92121
Phone: 858-362-6295
SAN DIEGO, CA 92121
Phone: 858-362-6295
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?6
Z-Score?18
Momentum?50
Short Sent.?30
Piotroski F-Score?1/9Weak
Altman Z-Score?1.37Distress
Confidence?65%Moderate
Short InterestSqueeze Risk
Short % of Float?30.59%Squeeze Risk
Short Interest?5.4M
Days to Cover?10.6
Free Float17.6M
Avg Daily Volume508.0K
Settlement Date2026-10-15
Financial Health
Current Ratio?7.58Strong
Quick Ratio?7.58Strong
Cash Ratio?5.96Strong
Debt/Equity?0.00Low
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score47/100
P/E?N/A▾
P/B?114.38HIGH▾
Peers100
S&P3
P/S?6.27FAIR▾
Peers100
S&P20
P/FCF?330.7PRICEY▾
Peers100
S&P3
EV/EBITDA?29.3HIGH▾
Peers100
S&P10
EV/Sales?5.20FAIR▾
Peers100
S&P34
Returns & Efficiency
ROE?-210.1%WEAK▾
S&P3
ROA?-8.1%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$4.4M
Enterprise Value?$1.2B
Fundamentals ratios updated end of day